The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy, safety, and immune activation with pegylated human IL-10 (AM0010) plus FOLFOX in metastatic pancreatic adenocarcinoma (PDAC).
 
J. Randolph Hecht
Stock and Other Ownership Interests - AllScripts; Cepheid; Cerner (I); ImmunoCellular Therapeutics; Inovio Pharmaceuticals; Juno Therapeutics (I); Medtronic (I); Nektar; Northwest Biotherapeutics; Novavax; Rexahn Pharmaceuticals; Sarepta Therapeutics (I); Zimmer Biomet
Consulting or Advisory Role - Amgen; ARMO BioSciences; Boston Biomedical; Celgene; Cornerstone Pharmaceuticals; Genentech; Halozyme; Insys Therapeutics; Lexicon; Novocure; Symphony Evolution
Research Funding - Amgen (Inst); Merrimack (Inst); OncoMed (Inst); Symphony Evolution (Inst)
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Research Funding - 3-V Biosciences; Abbvie; Aileron Therapeutics; ARMO BioSciences; AstraZeneca; Biothera; Celgene; Curegenix; Curis; DelMar Pharmaceuticals; eFFECTOR Therapeutics; EMD Serono; Fujifilm; Genmab; GlaxoSmithKline; Hutchison MediPharma; Incyte; Jounce Therapeutics; Kolltan Pharmaceuticals; Lilly; MedImmune; Millennium; Novartis; OncoMed; Precision Oncology; Regeneron; Strategia Therapeutics; Syndax; Taiho Pharmaceutical; Tesaro; Vegenics
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Millennium; Sarah Cannon Research Institute
 
Manish R. Patel
Honoraria - Bristol-Myers Squibb; Exelixis; Genentech; Gilead Sciences; Gilead Sciences; Gilead Sciences; Medivation
Speakers' Bureau - Bristol-Myers Squibb; Exelixis; Genentech; Gilead Sciences; Medivation
 
Raid Aljumaily
No Relationships to Disclose
 
Jeffrey R. Infante
Research Funding - Aileron Therapeutics (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Janssen Oncology (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche (Inst); Roche (Inst); Tesaro (Inst)
 
Aung Naing
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Baxter (I); EMD Serono; Healios; Incyte; Karyopharm Therapeutics; MedImmune; NCI; Novartis; Regeneron
Travel, Accommodations, Expenses - ARMO BioSciences
 
Deborah Jean Lee Wong
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - ARMO BioSciences; AstraZeneca/MedImmune; BioMed Valley Discoveries; Kura Oncology; Merck Serono; Merck Sharp & Dohme
 
Karen A. Autio
Research Funding - ARMO BioSciences; GlaxoSmithKline; Lilly; Pfizer
 
Navneet Ratti
Employment - ARMO BioSciences
 
Zev A. Wainberg
Consulting or Advisory Role - Amgen; Array BioPharma; Five Prime Therapeutics; Sirtex Medical
Speakers' Bureau - Genentech
Research Funding - Biomarin (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Amgen; Genentech
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TG Therapeutics (Inst)
 
Shubham Pant
Consulting or Advisory Role - Celgene; Halozyme
 
Gail Linda Brown
Employment - ARMO BioSciences
 
Peter Van Vlasselaer
Employment - ARMO BioSciences
Leadership - ARMO BioSciences
Stock and Other Ownership Interests - ARMO BioSciences
 
Martin Oft
Employment - ARMO BioSciences
 
Kyriakos P. Papadopoulos
Research Funding - Abbvie (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Onyx (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst)